Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Nlr Outperforms Low Hemoglobin And High Platelet Count As Predictive And Prognostic Biomarker In Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors

NLR Outperforms Low Hemoglobin and High Platelet Count as Predictive and Prognostic Biomarker in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Matthew Young1, Jose C Tapia2, Bernadett Szabados1

  • 1Barts ECMC, Barts Cancer Institute, Queen Mary University London, London, United Kingdom.

Clinical Genitourinary Cancer
|April 14, 2024

Related Experiment Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K

View abstract on PubMed

Summary
This summary is machine-generated.

Monitoring neutrophil-lymphocyte ratio (NLR), hemoglobin, and platelet counts during immune checkpoint inhibitor (ICI) therapy can predict outcomes in metastatic renal cell carcinoma (RCC). An NLR of 3 or higher after 12 weeks indicates a poorer prognosis.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biomarker Discovery

Background:

  • Reliable biomarkers for predicting response to immune checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC) are needed.
  • Previous studies suggest a high pretreatment neutrophil-lymphocyte ratio (NLR) is a negative prognostic factor in RCC, but a defined clinical cutoff is lacking.

Purpose of the Study:

  • To investigate the predictive and prognostic value of routine hematologic biomarkers, including NLR, in patients with metastatic clear cell RCC (ccRCC) receiving first-line ICI-based therapy.
  • To establish clinically useful cutoffs for these biomarkers in predicting treatment response and survival.

Main Methods:

  • Retrospective analysis of 132 treatment-naive metastatic ccRCC patients receiving first-line ICI-based therapy (anti-PD-1/PD-L1 alone or combined with anti-CTLA-4 or VEGF-TKI).
Keywords:
Dynamic biomarkersImmunotherapyKidney CancerRenal cell carcinoma

Related Experiment Videos

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

4.9K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.6K
  • Collection of platelet, hemoglobin, neutrophil, and lymphocyte counts at baseline and 12 weeks post-treatment initiation.
  • Assessment of radiologic response at 12 weeks and overall survival (OS).

    • Main Results:

    • Low hemoglobin, high platelet count, and NLR ≥3 at 12 weeks were significant negative predictive biomarkers.
    • Patients with low hemoglobin, high platelets, or NLR ≥3 at 12 weeks had significantly shorter median OS.
    • NLR ≥3 at 12 weeks remained a significant predictor in IMDC-risk adjusted analysis (OR 2.11, P = .003).
    • A dynamic decrease in NLR during therapy correlated with longer OS; normalization of NLR in patients with baseline elevation improved OS.

    Conclusions:

    • Neutrophil-lymphocyte ratio (NLR) ≥3, low hemoglobin, and elevated platelet count at 12 weeks are negative prognostic and predictive indicators for metastatic RCC patients on first-line ICI therapy.
    • Monitoring these routine hematologic biomarkers during therapy provides valuable predictive and prognostic information beyond baseline assessments.
    • Normalization of NLR during treatment is associated with improved overall survival and treatment response.
    Survival